Bitwise Crypto Industry Innovators ETF (ARCA: BITQ)

最新ニュース Bitwise Crypto Industry Innovators ETF (ARCA:BITQ)

Technology

Financial Services

Other

Consumer Cyclical

The Fund invests in securities comprising the Index and in depositary receipts representing securities of the Index. The Index was designed by Bitwise Index Services, LLC (the Index Sponsor) to measure the performance of companies involved in servicing the crypto currency markets, including crypto mining firms, crypto mining equipment suppliers, crypto financial services companies, or other financial institutions servicing primarily crypto-related clientele (i.e., the crypto ecosystem). Under normal circumstances, the Fund invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in securities of Crypto Innovators.

Marathon Patent Group Inc.

Coinbase Global, Inc.

Microstrategy Inc

Terawulf Inc

Northern Data Ag

Iris Energy Ltd

Core Scientific Inc

Cipher Mining Inc

Cleanspark Inc.

Galaxy Digital Holdings Ltd

Bitwise Crypto Industry Innovators ETF

News

CNDT

Conduent Sees FY25 Revenues Of $3.176B Vs. $3.280B Estimate

WIIM

BZAI

Blaize Holdings shares are trading higher after DA Davidson initiated coverage on the stock with a Buy rating and announced a price target of $10.

Planet Fitness, Inc. (NYSE:&nbsp;PLNT), one of the largest and fastest-growing franchisors and operators of fitness centers with more members than any other fitness brand, announced today that it has realigned its leadership team to support the Company's strategic imperatives and propel the brand forward. The following appointments will take effect on March 3, 2025:
Bill Bode, currently Division President, U.S. Franchise, will move into the newly-created Chief Operating Officer role and will oversee operations for both franchise and corporate clubs.
Jennifer Simmons, currently Division President, Corporate Clubs, will move into the newly-created Chief Strategy Officer role.
As Chief Operating Officer, Mr. Bode will be responsible for bringing to life the Company's non-intimidating, high-value member experience in Planet Fitness clubs. Mr. Bode has been with the Company for 8 years and will continue to report to CEO Colleen Keating.
As Chief Strategy Officer, Jennifer Simmons will be responsible for ensuring a data-driven approach to support the execution of the Company's strategic imperatives, identifying emerging trends, and ensuring the organization is well-positioned to remain the fitness category leader. Ms. Simmons has been with the Company for 11 years and will continue to report to Ms. Keating.

Management

PLNT

Planet Fitness's Bill Bode, Currently Division President, U.S. Franchise, Will Move Into The Newly-Created COO Role And Will Oversee Operations For Both Franchise And Corporate Clubs

Contracts

NXPL

NextPlat Corp's Subsidiary Global Telesat Communications Has Been Awarded A New Satellite-Based Asset Tracking Services Contract From A Global Humanitarian Aid Customer

Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), today announced that funds managed by Apollo affiliates (the "Apollo Funds") have acquired a majority interest in Bold Production Services, LLC ("Bold" or the "Company"), a provider of production-linked, contracted natural gas treatment solutions that enable the downstream use of natural gas, while reducing excess emissions and waste through proprietary equipment design.

Apollo Funds Acquire Bold Production Services; No Financial Terms Disclosed

Biotech

General

URGN

UroGen Highlights Publication From Long-Term follow-Up Study With JELMYTO Showing Median Duration Of Response Of 47.8 Months

Conduent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 600 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $800.000 million which missed the analyst consensus estimate of $809.667 million by 1.19 percent. This is a 16.05 percent decrease over sales of $953.000 million the same period last year.

Earnings

Earnings Misses

Conduent Q4 2024 Adj. EPS $(0.15) Misses $(0.09) Estimate, Sales $800.000M Miss $809.667M Estimate

REPL

Replimune Group Q3 EPS $(0.79) Misses $(0.71) Estimate

INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

Barrington Research analyst Kevin Steinke maintains Kelly Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KELYA#NASDAQ">KELYA</a>) with a Outperform and maintains $25 price target.

Price Target

Analyst Ratings

KELYA

Barrington Research Maintains Outperform on Kelly Services, Maintains $25 Price Target

Morgan Stanley analyst Erin Wright maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $301 to $285.

Morgan Stanley Maintains Equal-Weight on Humana, Lowers Price Target to $285

KALA BIO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017.

KALA

KALA BIO Announces The Resignation Of CEO Mark Iwicki, And The Appointment Of Todd Bazemore, KALA's President And COO, As Interim CEO, Effective Immediately

Advanced Environmental Recycling Technologies

AERT

Aeries Technology Appoints Ajay Khare As CEO, Succeeding Sudhir Panikassery

Genius Group Calls For An EGM For Shareholders to Authorize Up To 20% Share Capital Buyback; Co. Also Votes To Cancel Rights Offering

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) with a Buy and maintains $9 price target.

KAPA

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

Morgan Stanley analyst Angel Castillo maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Equal-Weight and lowers the price target from $28 to $24.

Morgan Stanley Maintains Equal-Weight on Kennametal, Lowers Price Target to $24

Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of innovative health solutions today announced that it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian influenza viruses (H5N1), specifically within the poultry industry.
The Company has engaged Vipragen Biosciences, an AAALAC-accredited preclinical Contract Research Organization (CRO) based in Mysuru, India ("Vipragen"), to conduct independent efficacy studies aimed at developing an antiviral solution for respiratory illnesses in humans. These studies are based on the Company's acquisition of patented respiratory illness prevention technology from IntraMont Technologies, Inc. ("IntraMont"). Phase I animal studies have already demonstrated significant efficacy in reducing lung viral load, and the compounds are now advancing into Phase II animal studies.
Mangoceuticals is leveraging this same technology to assess the feasibility of a drinking water-based application for poultry. The study is planned to focus on testing the efficacy of this solution when administered through drinking water and evaluating any necessary modifications to optimize its effectiveness in preventing avian flu infections among poultry populations.
Unlike traditional approaches that rely on synthetic vaccines or pharmaceutical treatments, Mangoceuticals' antiviral technology leverages Generally Recognized as Safe (GRAS) ingredients added to poultry drinking water. This method, we believe, may offer a simple, compliant, and non-pharmaceutical way to strengthen immune defenses in poultry. Following the Phase I animal studies, which concluded in late December, and pending promising results from the ongoing Phase II studies, though no assurances can be made, the Company believes this solution has the potential to be an effective tool in reducing the spread of H5N1 avian flu.
The ongoing avian flu outbreak has inflicted catastrophic losses on the poultry industry, leading to the culling of more than <a href="https://www.globenewswire.com/Tracker?data=cAiqJCym-e-4Hcnmx_SxEqLfzvB3i3c_LirGiQK5_ssIKpKjQCD0yIAS7jx61pHifx_fiT7sk2LhROmuyaEk7jEiibn13K9c_t7cUOTbFROZf4x_cLhRKc4fYiwS8ykVmRkpsEfbIqy7l3e0Rww61P3OYnZ5U_BeDvNcuC48ohA=">148 million birds</a> in the United States alone since 2022. These aggressive containment measures have crippled egg and poultry production, disrupted global supply chains, and sent consumer prices soaring. As of December 2024, the <a href="https://www.globenewswire.com/Tracker?data=_ZzFGKAcV97yscC4xdrPNMRsyS3qnJkYLAHH9QgZXyFrstujmG1vUTUCn9d1-9v4GGKUcR0SW-7kLWqKRsy3xf11H8KjzVz42n2XdP1ztYH40SjNNGn-yBl9P-_eqvZhj1_FxCBSz2Sv5SeRZRoZB6Bva3WI8YzD-rdPltO5v3lNXWV-YnTw3jFJ2IKBdVVc6pJulMwAZmN_kmcxeM9kOQS2xkxCqzVUT1nEaY98pCk=">national average price of eggs</a> hit $4.15 per dozen, with forecasts predicting an additional 20% increase in 2025.
In addition to direct losses from outbreaks, farms are extending significant amounts of resources on biosecurity measures and disease prevention strategies to protect flocks. Despite these costly efforts, avian flu remains a persistent threat, requiring a more effective and cost-efficient approach. Mangoceuticals' water-based antiviral technology aims to significantly reduce these expenses by hopefully providing a proactive, scalable, and easily deployable solution to help prevent infections before they spread.

MGRX

Mangoceuticals Announces Advancement in Avian Flu Prevention with Water-Based Antiviral for Poultry Using Patented Technology from IntraMont; Efficacy Demonstrated in Phase I Animal Studies, Now Entering Phase II

Throughout the last three months, 5 analysts have evaluated Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $35.8, with a high estimate of $40.00 and a low estimate of $28.00. This upward trend is apparent, with the current average reflecting a 2.87% increase from the previous average price target of $34.80.
<img src="https://www.benzinga.com/files/images/story/2025/1739365294_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Lincoln National among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lincoln National. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lincoln National compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Lincoln National's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lincoln National's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lincoln National analyst ratings.</a>
<h2>Unveiling the Story Behind Lincoln National</h2>
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
<h3>Lincoln National: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Lincoln National's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.66%. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Lincoln National's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lincoln National's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -7.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Lincoln National's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.14%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Lincoln National's debt-to-equity ratio stands notably higher than the industry average, reaching 0.75. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Lincoln National Stock: Analyst Perspectives (5 Ratings)

During the last three months, 9 analysts shared their evaluations of Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $103.67, a high estimate of $118.00, and a low estimate of $94.00. This upward trend is apparent, with the current average reflecting a 0.16% increase from the previous average price target of $103.50.
<img src="https://www.benzinga.com/files/images/story/2025/1739365273_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Aflac. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$107.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Aflac. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aflac compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Aflac's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Aflac's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aflac analyst ratings.</a>
<h2>Unveiling the Story Behind Aflac</h2>
Aflac Inc offers supplemental health insurance and life insurance in United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling majority of its policies directly to consumers at their places of work and also reaches out to its customers out of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
<h3>Key Indicators: Aflac's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Aflac's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -39.69%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3.06%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Aflac's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.37%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Aflac's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Aflac Stands With Analysts

Benchmark analyst David Williams maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $90 to $60.

Benchmark Maintains Buy on ON Semiconductor, Lowers Price Target to $60

George Selgin On Strategic Bitcoin Reserves, Debanking, And The Fed's Framework Review

Sanctions? Russia is now using bitcoin for international trade

Bitcoin Continues Breaking Minds And Models

What Trump's Presidency Will Mean For Bitcoin

Musk discussing blockchain use at Department of Government Efficiency

Trump meme coin 'hysteria' is more 'evidence of froth in asset markets' - Moody's

Above The Noise: Is The Worst Of Policy Uncertainty Behind Us?

Horizon Kinetics Founders Letter 2025

Trump is fueling a crypto bubble that 'could wreak havoc' – Elliott

Memecoins: Anyone's Guess As To What Will Happen Next, But It Feels Like It's Going To Be Wild

Comments

Bitwise Crypto Industry Innovators ETF

ニュース

最新ニュース Bitwise Crypto Industry Innovators ETF (ARCA:BITQ)

ニュース

パートナーシップ

ベンジンガ・グローバル